Crevast 20 mg is a selective, competitive prescription lipid-lowering medication containing Rosuvastatin (as rosuvastatin calcium). It belongs to the class of medications known as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly referred to as statins.
Crevast 20 mg is indicated as an adjunct to diet and therapeutic lifestyle changes for the treatment of primary hyperlipidemia, mixed dyslipidemia, and hypertriglyceridemia in adult patients. Furthermore, it is clinically prescribed to slow the progression of atherosclerosis and reduce the risk of major cardiovascular events—such as myocardial infarction, stroke, and arterial revascularization procedures—in individuals with elevated cardiovascular risk profiles.
Active Ingredient & Pharmacological Mechanism
Primary Active Ingredient
Rosuvastatin Calcium (20 mg): A synthetic lipid-regulating agent that works directly within hepatic tissue (the liver) to alter blood lipid concentration profiles.
Mechanism of Action
HMG-CoA Reductase Inhibition: Rosuvastatin selectively and competitively inhibits HMG-CoA reductase, the rate-limiting enzyme responsible for converting HMG-CoA to mevalonate, an essential precursor in hepatic cholesterol biosynthesis.
Upregulation of Hepatic LDL Receptors: By decreasing intracellular cholesterol concentrations in liver cells, Crevast increases the expression of low-density lipoprotein (LDL) cell-surface receptors on hepatocytes.
Enhanced LDL Clearance: The increased density of hepatic LDL receptors accelerates the uptake and catabolism of circulating LDL particles from the bloodstream, thereby lowering serum concentrations of total cholesterol and LDL cholesterol.
Reduction of Triglycerides & ApoB: Crevast decreases hepatic synthesis of very-low-density lipoprotein (VLDL) and apolipoprotein B-100 (ApoB), while simultaneously inducing a moderate increase in high-density lipoprotein cholesterol (HDL-C).
Key Medical Indications & Clinical Benefits
Reduction of Low-Density Lipoprotein (LDL-C): Significantly lowers serum levels of "bad" cholesterol in patients with primary hypercholesterolemia.
Triglyceride Modulation: Reduces circulating blood triglycerides (TG) and apolipoprotein B (ApoB) levels.
Elevation of High-Density Lipoprotein (HDL-C): Promotes a modest increase in "good" cholesterol, optimizing the total cholesterol-to-HDL ratio.
Cardiovascular Risk Reduction: Lowering atherogenic lipoproteins slows plaque accumulation within vascular walls, helping mitigate the long-term risk of heart attack, stroke, and angina.
Management of Homozygous Familial Hypercholesterolemia: Used as an adjunct to other lipid-lowering treatments (or when such treatments are unavailable) in hereditary cholesterol disorders.
Usage Instructions & Dosage Protocol
Important: Crevast 20 mg is a prescription-only medication. Exact dosage and administration schedule must be determined by a licensed physician based on individual patient lipid panels and cardiovascular risk assessment.
Standard Administration: Take one 20 mg tablet orally once daily.
Timing: Can be taken at any time of day, with or without food. However, taking the tablet at the same time each day helps maintain consistent therapeutic drug levels.
Swallowing Instructions: Swallow the tablet whole with a glass of water. Do not crush, chew, or divide the tablet.
Concomitant Dietary Measures: Patients should remain on a standard cholesterol-lowering diet throughout the duration of treatment.
Missed Dose: If a dose is missed, take the next scheduled dose at the normal time. Do not take two doses simultaneously to make up for a missed tablet.
Safety Precautions, Warnings & Contraindications
Absolute Contraindications
Pregnancy & Lactation: Crevast is strictly contraindicated in pregnant or breastfeeding women. Cholesterol and lipid synthesis products are essential for fetal development; statin therapy may cause fetal harm.
Active Liver Disease: Contraindicated in patients with active hepatic disease, including unexplained, persistent elevations in serum transaminases (AST/ALT).
Severe Renal Impairment: Not recommended for patients with severe kidney dysfunction (creatinine clearance less than 30 mL/min).
Hypersensitivity: Known allergy or severe adverse reaction to rosuvastatin or any inactive ingredient in the formulation.
Clinical Precautions & Risk Factors
Myopathy & Rhabdomyolysis: Statins carry a risk of skeletal muscle toxicity. Patients should immediately report unexplained muscle pain, tenderness, weakness, or dark-colored urine to their healthcare provider. Risk increases with advanced age (greater than 65 years), untreated hypothyroidism, renal impairment, or co-administration with interacting medications.
Hepatic Monitoring: Liver function tests (transaminase levels) should be performed prior to initiating therapy and as clinically indicated during treatment.
Drug Interactions: Caution and dosage adjustments are required when co-administered with cyclosporine, gemfibrozil, certain HIV/HCV protease inhibitors, blood thinners (such as warfarin), or antacids containing aluminum and magnesium (which should be taken at least 2 hours after Crevast).
Glycemic Effects: Increases in HbA1c and fasting serum glucose levels have been observed with HMG-CoA reductase inhibitors. Patients with risk factors for diabetes should be monitored periodically.
Product Storage & Handling
Storage Temperature: Store below 30°C (86°F) in a cool, dry place.
Packaging Protection: Keep tablets inside the original blister packaging to protect from light and excessive moisture.
Safety: Keep strictly out of the reach and sight of children.
Medication
